📰 Nasdaq Rlmd News
Nasdaq Rlmd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Rlmd. Real-time updates on events, politics, business and more.
April 1, 2024
Parsons Capital Management Inc. RI reduced its stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 949,841 shares of the company’s stock after selling 24,241 shares during […]
February 18, 2024
Silverarc Capital Management LLC acquired a new stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the company’s stock, valued at approximately $300,000. Silverarc Capital Management LLC owned […]
February 18, 2024
Silverarc Capital Management LLC acquired a new position in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 100,000 shares of the company’s stock, valued at approximately $300,000. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the […]
February 1, 2024
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CFO Maged Shenouda acquired 6,875 shares of Relmada Therapeutics stock in a transaction dated Wednesday, January 31st. The stock was bought at an average price of $4.06 per share, with a total value of $27,912.50. Following the completion of the purchase, the chief financial officer now directly […]
February 1, 2024
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) insider Chuck Ence bought 14,500 shares of the stock in a transaction dated Tuesday, January 30th. The stock was purchased at an average cost of $3.87 per share, for a total transaction of $56,115.00. Following the acquisition, the insider now owns 25,300 shares of the company’s stock, […]
February 1, 2024
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CEO Sergio Traversa bought 31,541 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average price of $3.71 per share, with a total value of $117,017.11. Following the completion of the purchase, the chief executive officer […]
February 1, 2024
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) CFO Maged Shenouda bought 6,875 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were purchased at an average price of $4.06 per share, with a total value of $27,912.50. Following the completion of the acquisition, the chief financial officer now owns […]
January 28, 2024
Parsons Capital Management Inc. RI increased its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) by 11.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 974,082 shares of the company’s stock after purchasing an additional 100,770 shares during the quarter. Parsons […]
January 1, 2024
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 638,800 shares, a decrease of 26.2% from the November 30th total of 865,800 shares. Based on an average daily volume of 172,800 shares, the days-to-cover ratio […]
December 6, 2023
Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) by 17.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 338,945 shares of the company’s stock after purchasing an additional 49,999 shares during the quarter. […]